FY2017 Earnings Estimate for Endo International plc – Issued By Leerink Swann (ENDP)
Endo International plc – (NASDAQ:ENDP) (TSE:ENL) – Research analysts at Leerink Swann issued their FY2017 EPS estimates for shares of Endo International in a research note issued on Tuesday. Leerink Swann analyst A. Fadia anticipates that the company will post earnings per share of $3.65 for the year. Leerink Swann currently has a “Outperform” rating and a $12.00 target price on the stock. Leerink Swann also issued estimates for Endo International’s Q4 2017 earnings at $0.57 EPS, Q1 2018 earnings at $0.72 EPS, Q2 2018 earnings at $0.79 EPS, FY2018 earnings at $3.02 EPS, FY2019 earnings at $3.20 EPS, FY2020 earnings at $2.92 EPS and FY2021 earnings at $2.73 EPS.
Endo International (NASDAQ:ENDP) (TSE:ENL) last issued its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million during the quarter, compared to analysts’ expectations of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. Endo International’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.01 EPS.
Shares of Endo International (NASDAQ ENDP) opened at $8.73 on Friday. Endo International has a fifty-two week low of $5.77 and a fifty-two week high of $17.63. The company has a debt-to-equity ratio of 10.78, a current ratio of 1.08 and a quick ratio of 0.86. The firm has a market capitalization of $1,978.56, a P/E ratio of -0.39, a price-to-earnings-growth ratio of 2.99 and a beta of 0.59.
Several large investors have recently made changes to their positions in ENDP. Sivik Global Healthcare LLC bought a new position in shares of Endo International in the 2nd quarter worth approximately $2,793,000. Diamond Hill Capital Management Inc. increased its position in Endo International by 46.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock valued at $6,138,000 after buying an additional 228,426 shares in the last quarter. River & Mercantile Asset Management LLP increased its position in Endo International by 116.3% during the 3rd quarter. River & Mercantile Asset Management LLP now owns 358,540 shares of the company’s stock valued at $3,071,000 after buying an additional 192,790 shares in the last quarter. Van ECK Associates Corp increased its position in Endo International by 67.1% during the 3rd quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock valued at $2,921,000 after buying an additional 136,873 shares in the last quarter. Finally, Quantitative Investment Management LLC bought a new position in Endo International during the 2nd quarter valued at approximately $1,344,000. 93.06% of the stock is owned by hedge funds and other institutional investors.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.